Clinical TrialsArbutus reported further follow-up data from the Phase 2a IM-PROVE I study, showing six patients in the A1 and A2 cohorts reached undetectable levels of HBsAg as of the end of the 24-week period of nuc-only treatment and have achieved seroconversion.
EarningsThe company ended the quarter with cash, cash equivalents, and marketable securities of $148.5 million compared to $132.3 million at the end of 2023.
LegalPositive litigation updates and ABUS' commitment to not use its ATM have driven stock outperformance.